Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Michelle A. Fanale; Steven M. Horwitz; Andres Forero-Torres; Nancy L. Bartlett; Ranjana H. Advani; Barbara Pro; Robert W. Chen; Andrew Davies; Tim Illidge; Mayur Uttarwar; Shih-Yuan Lee; Hong Ren; Dana A. Kennedy; Andrei R. Shustov

doi:10.1182/blood-2017-12-821009

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Michelle A. Fanale, Steven M. Horwitz, Andres Forero-Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Mayur Uttarwar, Shih-Yuan Lee, Hong Ren, Dana A. Kennedy, Andrei R. Shustov

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

See full text for abstract.

Original language	English
Pages (from-to)	2120-2124
Journal	Blood
Volume	131
Issue number	19
Early online date	5 Mar 2018
DOIs	https://doi.org/10.1182/blood-2017-12-821009
Publication status	Published - 10 May 2018

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2017-12-821009

Cite this

Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., Chen, R. W., Davies, A., Illidge, T., Uttarwar, M., Lee, S.-Y., Ren, H., Kennedy, D. A., & Shustov, A. R. (2018). Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood, 131(19), 2120-2124. https://doi.org/10.1182/blood-2017-12-821009

@article{3584c6a1d4ed49d186c764135e6d3ea9,

title = "Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas",

abstract = "See full text for abstract.",

author = "Fanale, {Michelle A.} and Horwitz, {Steven M.} and Andres Forero-Torres and Bartlett, {Nancy L.} and Advani, {Ranjana H.} and Barbara Pro and Chen, {Robert W.} and Andrew Davies and Tim Illidge and Mayur Uttarwar and Shih-Yuan Lee and Hong Ren and Kennedy, {Dana A.} and Shustov, {Andrei R.}",

year = "2018",

month = may,

day = "10",

doi = "10.1182/blood-2017-12-821009",

language = "English",

volume = "131",

pages = "2120--2124",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

number = "19",

}

Fanale, MA, Horwitz, SM, Forero-Torres, A, Bartlett, NL, Advani, RH, Pro, B, Chen, RW, Davies, A, Illidge, T, Uttarwar, M, Lee, S-Y, Ren, H, Kennedy, DA & Shustov, AR 2018, 'Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas', Blood, vol. 131, no. 19, pp. 2120-2124. https://doi.org/10.1182/blood-2017-12-821009

TY - JOUR

T1 - Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

AU - Fanale, Michelle A.

AU - Horwitz, Steven M.

AU - Forero-Torres, Andres

AU - Bartlett, Nancy L.

AU - Advani, Ranjana H.

AU - Pro, Barbara

AU - Chen, Robert W.

AU - Davies, Andrew

AU - Illidge, Tim

AU - Uttarwar, Mayur

AU - Lee, Shih-Yuan

AU - Ren, Hong

AU - Kennedy, Dana A.

AU - Shustov, Andrei R.

PY - 2018/5/10

Y1 - 2018/5/10

N2 - See full text for abstract.

AB - See full text for abstract.

U2 - 10.1182/blood-2017-12-821009

DO - 10.1182/blood-2017-12-821009

M3 - Article

SN - 0006-4971

VL - 131

SP - 2120

EP - 2124

JO - Blood

JF - Blood

IS - 19

ER -

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this